London, United Kingdom · Founded 2007 · Privately Held (backing)
Developer of antifungal drugs designed to treat acute and chronic respiratory diseases. Pulmocide is based in London, United Kingdom and was founded in 2007. Its last reported valuation was $292 million in Sep 2025. It has raised $268 million.
Last reported valuation
$291.6M
Oct 2026
Priced at
—
Total raised
$267.6M
Last round
—
Cap table — not yet on record
Pulmocide's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Pulmocide with a free account
·The complete investor list: 15 names
·Watch Pulmocide: the Monday email on marks, rounds and moves
